Inhibitors of apoptosis: clinical implications in cancer

被引:126
作者
Mohamed, Mervat S. [1 ,2 ]
Bishr, Mai K. [3 ]
Almutairi, Fahad M. [1 ]
Ali, Ayat G. [4 ]
机构
[1] Univ Tabuk, Dept Biochem, Fac Sci, Tabuk, Saudi Arabia
[2] Cairo Univ, Dept Chem, Fac Sci, Biochem Special, Giza, Egypt
[3] CCHE, Dept Radiotherapy, Cairo, Egypt
[4] El Sahel Teaching Hosp, Dept Biochem, Cairo, Egypt
关键词
Apoptosis; Inhibitor of apoptosis; Caspases; Smac mimetics; Cancer target therapy; X-LINKED-INHIBITOR; NF-KAPPA-B; ACUTE MYELOID-LEUKEMIA; SEPANTRONIUM BROMIDE YM155; UBIQUITIN-PROTEIN LIGASE; SMAC-MIMETIC BIRINAPANT; TRAIL-INDUCED APOPTOSIS; MULTICENTER PHASE-II; INDUCED CELL-DEATH; DOWN-REGULATION;
D O I
10.1007/s10495-017-1429-4
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Inhibitor of apoptosis (IAP) family comprises a group of endogenous proteins that function as main regulators of caspase activity and cell death. They are considered the main culprits in evasion of apoptosis, which is a fundamental hallmark of carcinogenesis. Overexpression of IAP proteins has been documented in various solid and hematological malignancies, rendering them resistant to standard chemotherapeutics and radiation therapy and conferring poor prognosis. This observation has urged their exploitation as therapeutic targets in cancer with promising pre-clinical outcomes. This review describes the structural and functional features of IAP proteins to elucidate the mechanism of their anti-apoptotic activity. We also provide an update on patterns of IAP expression in different tumors, their impact on treatment response and prognosis, as well as the emerging investigational drugs targeting them. This aims at shedding the light on the advances in IAP targeting achieved to date, and encourage further development of clinically applicable therapeutic approaches.
引用
收藏
页码:1487 / 1509
页数:23
相关论文
共 287 条
[1]   Survivin Expression in Medulloblastoma: A Possible Marker for Survival [J].
Abdel-Aziz, Azza ;
Mohamed, Mie Ali Ali ;
Akl, Fatma Mohamed Farouk ;
Taha, Ahmed Nageeb M. .
PATHOLOGY & ONCOLOGY RESEARCH, 2013, 19 (03) :413-419
[2]   Expression of inhibitor of apoptosis proteins in B-cell non-Hodgkin and Hodgkin lymphomas [J].
Akyurek, Nalan ;
Ren, Yongsheng ;
Rassidakis, Georgios Z. ;
Schlette, Ellen J. ;
Medeiros, L. Jeffrey .
CANCER, 2006, 107 (08) :1844-1851
[3]   A novel adamantane thiadiazole derivative induces mitochondria-mediated apoptosis in lung carcinoma cell line [J].
Ali, Ayat G. ;
Mohamed, Magda F. ;
Abdelhamid, Abdou O. ;
Mohamed, Mervat S. .
BIOORGANIC & MEDICINAL CHEMISTRY, 2017, 25 (01) :241-253
[4]   Livin/BIRC7 expression as malignancy marker in adrenocortical tumors [J].
Altieri, Barbara ;
Sbiera, Silviu ;
Della Casa, Silvia ;
Weigand, Isabel ;
Wild, Vanessa ;
Steinhauer, Sonja ;
Fadda, Guido ;
Kocot, Arkadius ;
Bekteshi, Michaela ;
Mambretti, Egle M. ;
Rosenwald, Andreas ;
Pontecorvi, Alfredo ;
Fassnacht, Martin ;
Ronchi, Cristina L. .
ONCOTARGET, 2017, 8 (06) :9323-9338
[5]   Survivin and IAP proteins in cell-death mechanisms [J].
Altieri, Dario C. .
BIOCHEMICAL JOURNAL, 2010, 430 :199-205
[6]   A Phase I Study of the SMAC-Mimetic Birinapant in Adults with Refractory Solid Tumors or Lymphoma [J].
Amaravadi, Ravi K. ;
Schilder, Russell J. ;
Martin, Lainie P. ;
Levin, Myron ;
Graham, Martin A. ;
Weng, David E. ;
Adjei, Alex A. .
MOLECULAR CANCER THERAPEUTICS, 2015, 14 (11) :2569-2575
[7]  
Amaravadi RK, 2013, J CLIN ONCOL, V31
[8]   A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma [J].
Ambrosini, G ;
Adida, C ;
Altieri, DC .
NATURE MEDICINE, 1997, 3 (08) :917-921
[9]  
[Anonymous], J CLIN ONCOL
[10]  
Antonaci A, 2008, ONCOL REP, V20, P63